N-[4-[4-(3,3-dimethylbutanoyl)piperazin-1-yl]phenyl]octanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-[4-[4-(3,3-dimethylbutanoyl)piperazin-1-yl]phenyl]octanamide
• 化学式: C₂₄H₃₉N₃O₂
• 分子量: 401.6
• InChiKey: SPTQOKQTCKDUPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  29
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Modulation of dynein in skin
  申请人：Avon Products, Inc.

  公开号：EP2889384A1

  公开（公告）日：2015-07-01

  Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that modulate dynein expression in the skin. Also provided are methods for screening for substances which modulate dynein expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin.

  本研究提供了预防、改善或减少皮肤老化迹象的方法，这些方法采用了可调节皮肤中染料蛋白表达的活性剂。此外，还提供了筛选可调节染料蛋白表达水平的物质的方法，以及使用筛选方案确定的活性剂治疗皮肤的方法。
• MODULATION OF DYNEIN IN SKIN
  申请人：Avon Products, Inc.

  公开号：EP2659004B1

  公开（公告）日：2017-08-30
• Method for identifying active agents for improving the aesthetic appearance of human skin
  申请人：Avon Products, Inc.

  公开号：EP2889384B1

  公开（公告）日：2016-09-28
• Modulation of Dynein in Skin
  申请人：ZHENG Qian

  公开号：US20120171133A1

  公开（公告）日：2012-07-05

  Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that modulate dynein expression in the skin. Also provided are methods for screening for substances which modulate dynein expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin.
• [EN] MODULATION OF DYNEIN IN SKIN<br/>[FR] MODULATION DE LA DYNÉINE DANS LA PEAU
  申请人：AVON PROD INC

  公开号：WO2012091832A2

  公开（公告）日：2012-07-05

  Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that modulate dynein expression in the skin. Also provided are methods for screening for substances which modulate dynein expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin.